Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many patients have received medicine funded by the Cancer Drugs Fund by medicine since 2016.
Since the new Cancer Drugs Fund began in July 2016, just over 17,600 patients have been registered to receive treatment for 48 medicines.
Below is a table showing the breakdown by medicine.
Drug | Number |
Atezolizumab | 34 |
Bendamustine | 2,321 |
Bevacizumab | 1,595 |
Blinatumomab | 29 |
Bortezomib | 105 |
Bosutinib | 39 |
Brentuximab | 346 |
Cabozantinib | 154 |
Carfilzomib | 45 |
Ceritinib | 15 |
Cetuximab | 1,708 |
Clofarabine | 82 |
Crizotinib | 127 |
Daratumumab | 35 |
Dasatinib | 107 |
Eribulin | 347 |
Everolimus | 370 |
Ibrutinib | 1,067 |
Ipilimumab/Nivolumab | 97 |
Ixazomib | 119 |
Lenvatinib | Fewer than 10 |
Nab-paclitaxel | 134 |
Nelarabine | 45 |
Nivolumab | 541 |
Obinutuzumab | 33 |
Olaratumumab | 199 |
Osimertinib | 255 |
Palbociclib | 413 |
Panitumumab | 392 |
Pemetrexed | 37 |
Pembrolizumab | 1,604 |
Pertuzumab | 1,739 |
Pegylated liposomal doxorubicin | 48 |
Pomalidomide | 380 |
Ponatinib | 88 |
Radium-223 Dichloride | 243 |
Regorafenib | 74 |
Ribociclib | 29 |
Sorafenib | 871 |
Sunitinib | 71 |
Talimogene laherparepvec | Fewer than 10 |
Temsirolimus | Fewer than 10 |
Trastuzumab Emtansine | 673 |
Trametinib/Dabrafenib | 172 |
Trifluridine and tipiracil | 444 |
Vandetanib | 40 |
Venetoclax | 118 |
Vismodegib | 217 |
Source: NHS England. Information provided from 31 July 2016 to end of January 2018 (latest data available).
Note:
Numbers lower than 10 are rounded-up to avoid releasing potentially patient identifiable data, as per NHS England’s data protection commitments.